Ibuprofen Kabi (Ibuprofen)

Ibuprofen inhibits both COX‑1 and COX‑2 enzymes, reducing the synthesis of prostaglandins that mediate pain, fever, and inflammation. By lowering prostaglandin levels, it diminishes peripheral sensitization of pain receptors, resets the hypothalamic temperature set‑point, and limits inflammatory exudate formation.

The dosage of Ibuprofen Kabi is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and response to therapy. Healthcare professionals set the appropriate infusion rate and total daily amount according to established hospital protocols.

Safety data for intravenous ibuprofen in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made by the treating physician in consultation with obstetric specialists.

To request Ibuprofen Kabi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Compared with other IV NSAIDs, ibuprofen offers a well‑characterized safety profile and effective analgesia at lower cardiovascular risk than selective COX‑2 inhibitors. Unlike opioids, it does not cause respiratory depression, but it shares typical NSAID cautions such as renal and gastrointestinal considerations.

Ibuprofen Kabi must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Inspect the product before use and discard any vial that appears cloudy or contains particles.

The medication is supplied as a sterile injection solution for intravenous infusion. It is administered by a healthcare professional through a dedicated IV line, typically diluted in compatible IV fluids and infused over a short period as directed by the prescribing protocol.

Serious risks include severe allergic reactions such as anaphylaxis, gastrointestinal bleeding or ulcer perforation, acute kidney injury, and cardiovascular events like myocardial infarction or stroke. Prompt recognition and management of these events are essential, and patients should be monitored closely during therapy.

Ibuprofen Kabi should be avoided in patients with known hypersensitivity to ibuprofen or other NSAIDs, active peptic ulcer disease, severe uncontrolled heart failure, significant renal impairment, and in those receiving anticoagulant therapy where bleeding risk is high, unless the prescriber determines that benefits outweigh risks.